Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Chris Labaki(Beth Israel Deaconess Medical Center), Rana R. McKay(University of California San Diego Medical Center), David Maj(University of Calgary), Caiwei Zhong(Dana-Farber Cancer Institute), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Zeynep İrem Özay(University of Utah), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Kosuke Takemura(Japanese Foundation For Cancer Research), W. Xie(Dana-Farber Cancer Institute), Anvisha Upadhyaya(UC San Diego Health System), Y. Chen(University of California San Diego Medical Center), Marc Eid(Harvard University), Daniel Yick Chin Heng(University of Calgary), Eddy Saad(Dana-Farber Cancer Institute), Naveen S. Basappa(University of Alberta), Razane El Hajj Chehade(Dana-Farber Cancer Institute), J. Connor Wells(BC Cancer Agency), Neeraj Agarwal(University of Utah), Toni K. Choueiri(Dana-Farber Cancer Institute), Martín Zarbá(University of Calgary)
Cited by 0
Related Papers
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
|Journal of Clinical Oncology|2024|170
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136